A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary) ; Tobemstomig (Primary) ; Ipilimumab; Nivolumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Morpheus-Melanoma
- Sponsors Roche
- 30 Apr 2024 Status changed from recruiting to completed.
- 25 Apr 2024 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 14 Aug 2023 Planned primary completion date changed from 18 Oct 2024 to 19 Jan 2025.